Drug Profile
ENMD 2076
Alternative Names: ENMD-2076; ENMD-981693; MKC-1693Latest Information Update: 11 May 2020
Price :
$50
*
At a glance
- Originator Miikana Therapeutics
- Developer CASI Pharmaceuticals
- Class Antineoplastics; Piperazines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Aurora kinase A inhibitors; Fms-like tyrosine kinase 3 inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Cancer; Haematological malignancies; Liver cancer; Multiple myeloma; Ovarian cancer; Soft tissue sarcoma; Triple negative breast cancer
Most Recent Events
- 16 Mar 2020 ENMD 2076 is available for licensing as of 16 Mar 2020. https://www.casipharmaceuticals.com/
- 16 Mar 2020 Discontinued - Phase-I for Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 16 Mar 2020 Discontinued - Phase-II for Liver cancer (Late-stage disease) in USA (PO)